Market News & Trends
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase 3 Study
Celsion Corporation recently announces the prescribed number of events has been reached for the first prespecified interim analysis of the OPTIMA Phase 3 Study with…
Eureka Therapeutics Announces Initiation of Phase 1/2 Clinical Trial
Eureka Therapeutics, Inc. recently announced initiation of Phase 1/2 clinical trial of ET140202 ARTEMIS T-cell therapy in liver cancer at City of Hope, a world-renowned…
Cytel Launches East On Demand Bringing Adaptive Clinical Trial Design Capabilities to Wider Biopharma Audience
Cytel Inc. recently announced that it will launch East On Demand at the annual Joint Statistical Meetings (JSM) 2019 (July 27-August 1, Denver, CO). Offered…
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study
Oncternal Therapeutics, Inc. recently announced it has opened for enrollment its randomized Phase 2 study of cirmtuzumab, a ROR1-targeted monoclonal antibody, combined with ibrutinib in…
Cambrex to Double Size of Edinburgh Solid Form Screening Facility
Cambrex Corporation, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it is…
Mino-Wrap to be Developed Through an IND Process
Citius Pharmaceuticals, Inc. recently reported the company's decision to develop Mino-Wrap as a drug through the Investigational New Drug (IND) process. The FDA's IND program…
Principia Announces Update to Ongoing Phase 2 Clinical Trial
Principia Biopharma Inc. recently announced updates to its immune thrombocytopenia (ITP) program for PRN1008. The ongoing open-label, dose-finding clinical trial investigating PRN1008 in patients with…
MariMed Signs Multi-State Licensing Agreement
MariMed Inc. recently announced a licensing agreement with Denver-based Binske, which offers an innovative range of diverse cannabis products. Under the terms of the agreements,…
Foamix Announces $64-Million Capital Financing Investment by Perceptive Advisors & OrbiMed
Foamix Pharmaceuticals Ltd. recently announced it has secured up to $64 million in financing from Perceptive Advisors and OrbiMed. The financing consists of term loans…
PROMETRIKA Partners With Comprehend to Enhance its Full-Service Clinical Trial Offering
PROMETRIKA, LLC and Comprehend Systems, Inc. recently announce a partnership that will provide innovative solutions to meet the evolving needs of biotech and pharmaceutical sponsors…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….